- Advanced BioNutrition Corp. (ABN), a leading provider of advanced stabilization and delivery solutions across the health and nutrition, agriculture, and biopharma industries, announced today that it is collaborating with Myron M. Levine, MD, DTPH, Simon and Bessie Grollman Distinguished Professor of Medicine at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health (CVD), to test a new formulation of a live oral Salmonella Paratyphi A vaccine to prevent paratyphoid fever.
- ABN’s breakthrough stabilization technology platform holds promise for reducing cold chain reliance and improving access to life-saving vaccines.
- The development of a non-refrigerated vaccine has the potential to significantly reduce the estimated 3.4 million cases of paratyphoid fever and approximately 322,000 deaths caused annually by Salmonella Paratyphi A, according to the World Health Organization.
685 West Baltimore Street, Room 480
Baltimore, MD 21201-1509
Baltimore, MD 21201-1509
Washington, DC 20037
© 2018. Coalition Against Typhoid. All Rights Reserved.